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Oculopharyngeal muscular dystrophy (OPMD) 
(OMIM #164300) is a late-onset (>45 years) myopathy 
characterised by progressive ptosis, dysphagia and 
varying degrees of proximal muscle weakness. The 
ptosis is mostly restricted to the levator palpebrae 
and later involves other extraocular muscles. Complete external 
ophthalmoplegia is rare. The dysphagia is initially for solids only, 
but steadily progresses to an extent that patients may become 
malnourished. In later life these patients may suffer from bouts of 
aspiration pneumonia. Although proximal muscle weakness, facial 
weakness and dysarthria may occur, smooth and cardiac muscles 
appear to be spared. Pathologically, intranuclear inclusions are 
observed in the muscle fibres.[1]
Early descriptions of families with ptosis and dysphagia drew 
attention to the hereditary basis of the disorder, and after the 1962 
publication by Victor et al.[2] the condition was recognised as a form 
of muscular dystrophy and given the name OPMD. The condition 
is mainly inherited in an autosomal dominant manner, although 
uncommon recessive forms have been described.[1]
OPMD has been recognised as a trinucleotide repeat expansion 
disorder.[3] The PABN1 gene, also known as PABP2, encoding the 
polyadenylate binding protein nuclear 1, has a polyalanine tract in 
the N-terminal end. The wild-type allele is (GCG)6(GCA)3GCG, 
adding up to a total of ten alanine residues (GCNs). Abnormal 
expansion of this tract results in OPMD.[3] The expansion usually 
occurs in the (GCG)6 repeat, but repeats of the (GCA)3 have been 
documented. Individuals with OPMD have expansions ranging from 
12 to 17 GCNs.[1] Normal PABN1 is a nuclear protein that is involved 
in the polyadenylation of messenger RNA.[4] It associates with RNA 
polymerase II during transcription and facilitates movement of 
the released transcript through the nuclear pore, thus acting as a 
molecular chaperone for the proper export of poly(A) RNA from 
the nucleus.[5] Additionally, PABN1 was found to bind to SKIP 
(ski-interacting protein), and together they directly control the 
expression of muscle-specific genes. Following on from this, Apponi 
et al.[6] demonstrated that the normal protein plays an important 
role in myoblast proliferation and differentiation, whereas the 
extended polyalanine tract causes clumping or the PABN1 protein 
and accumulation in the nuclei of the skeletal muscle fibres.[7] 
Recently Davies and Rubinsztein[8] reported that apoptosis is directly 
involved in the pathology of OPMD, and that it is a major contributor 
to the muscle dysfunction in the disease.
The incidence of OPMD varies widely, ranging from 1/200 000 in 
France to 1/600 in Israel (Bukhara Jewish population). The disease 
has been described in more than 35 countries worldwide, with some 
variations in clinical presentation.
To our knowledge, this is the first South African (SA) OPMD 
family to be described. We report on the clinical and molecular 
genetic characteristics of this family.
The proband was a 64-year-old woman who presented with 
ptosis, progressive dysphagia and some proximal weakness to the 
neurology outpatient department at Steve Biko Academic Hospital 
in Pretoria, SA. With the assistance of the patient, a family pedigree 
was drawn up and contact details of as many family members as 
possible were obtained. All were then contacted and invited to 
take part in this study. After informed consent had been obtained, 
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dysphagia, dysarthria and mild proximal weakness. High foot arches and absent ankle reflexes raised the possibility of peripheral neuropathy, 
but electromyography showed only mildly low sensory amplitudes, and myopathic units in two patients.
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four individuals were subsequently inter-
viewed and examined clinically, and had 
electromyographic (EMG) studies per-
formed. In addition, blood samples were 
taken from three individuals.
Genomic DNA was extracted from 
peripheral blood using standard protocols. 
Exon 1 of PABN1, containing the region 
where the GCN repeat is located, was ampli-
fied using primers previously described[9] 
with the Failsafe PCR Enzyme mix with 
buffer J (Epicentre Biotechnologies, USA). 
Cycle sequencing of the amplicons was 
performed with BigDyeV3.1 (Applied 
Biosystems, USA) and analysed on an ABI 
3130 (Applied Biosystems).
The study was approved by the Ethics 
Committee of the Faculty of Health Sciences, 
University of Pretoria.
Family pedigree
An abbreviated pedigree of this Afrikaner 
family is depicted in Fig. 1. The index patient 
(III:17) was one of a sibship of 18, eight 
of whom are affected with OPMD. Their 
mother (II:2) was affected from the age of 
approximately 40 years. Noteworthy is the 
offspring of III:2, an unaffected daughter, 
who happened to marry her maternal cousin 
(III:3) who had OPMD. Their children (IV:1 
and IV:2) inherited the disorder from their 
father.
Patient III:17
This 64-year-old woman reported that her 
first symptoms of ptosis had started at the 
age of about 40 years, but really interfered 
with her vision only 10 years later, when 
she needed eyelid surgery to correct the 
ptosis. Dysphagia was also present from 
age 40 years and progressed slowly up to a 
point where she now has to be very selective 
about the food she eats. On examination, she 
had normal higher functions (Mini Mental 
State Examination (MMSE) 27/30). She had 
dysarthria with somewhat nasal speech and 
often had to clear her throat while speaking. 
The range of eye movements was restricted, 
especially upwards in that she could not 
elevate her eyes beyond the neutral position. 
Ptosis was not prominent after the eyelid 
surgery. Mild facial weakness was present, 
as well as weakness of neck flexion (4/5) 
and mild proximal weakness in the upper 
and lower limbs. Deep tendon reflexes could 
only be elicited with augmentation, but ankle 
reflexes were absent. The patient had high-
arched feet, but the findings on sensory 
examination were unremarkable.
On EMG, peroneal, tibial and radial 
motor responses were normal. The sural 
response showed slightly low amplitude, as 
did the medial and lateral plantar responses. 
The peripheral autonomic sensory potentials 
(PASPs) were present, and the response to 
repetitive stimulation of the ulnar nerve was 
within normal limits. A needle examination 
showed normal motor units in the deltoid 
muscle. 
Patient III:9
This woman was 75 years old when examined. 
Her data were retrieved retrospectively 
from her neurologist’s patient record files 
because she lived far away. She had severe 
dysphagia and had lost 15 kg over the past 
few months. On examination, she had an 
almost total external ophthalmoplegia and 
ptosis, more marked on the left. There was 
weakness of the soft palate and tongue, and 
her speech was hoarse and dysarthric. Mild 
proximal and distal weakness was present, 
but this was difficult to interpret owing to 
her weak general condition. Findings on 
EMG conduction studies of the median 
and ulnar motor and sensory nerves were 
normal. Myopathic units were found in the 
deltoid muscle, and needle examination 
of the tongue revealed normal insertional 
activity and normal motor unit potentials. 
The findings on repetitive stimulation 
studies of the accessory nerve were also 
normal. The patient underwent insertion of 
a gastrostomy tube to facilitate feeding. 
Patient III:14
As with III:17, this 70-year-old woman’s 
ptosis had started at approximately 40 
years of age. She had experienced the first 
symptoms of dysphagia at around 50 years, 
after which it progressively worsened. 
Eyelid repair surgery had been performed 
twice in the past 20 years. On examination, 
higher mental functions were normal 
(MMSE 28/30), but the patient had marked 
dysarthria with prominent nasal speech and 
lip weakness; the eye movements were full 
except for some mild restriction of lateral 
gaze to both sides. There was asymmetry 
on elevation of the soft palate and severe 
dysphagia. She had a clearly myopathic 
face with weakness of the frontalis, levator 
palpebrae superioris and orbicularis oculi 
muscles and severe weakness of the upper 
lip levators and levator anguli oris. Limb 
weakness was very mild: the deltoids, 
pectorals, biceps, triceps and hip flexors and 














Fig. 1. Pedigree of SA Afrikaner family with OPMD.
Fig. 2. Sequence chromatograph of exon 1 of the PABN1 gene. The disease causing heterozygous expansion 
(GCG)11(GCA)3GCG (patient) is shown in the upper chromatograph. The lower chromatograph depicts 
a homozygous normal (GCG)6(GCA)3GCG tract in an unaffected individual.
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foot dorsiflexion and finger extension was also weak at grade 4/5. The 
deep tendon reflexes of the upper limbs were only present as a flicker 
with augmentation manoeuvres, the patella reflex was 2+/4, and the 
ankle reflexes were absent. The findings on sensory examination were 
normal. The patient also had high-arched feet.
EMG showed normal responses of the peroneal, tibial and radial 
motor nerves, the medial and lateral plantar responses showed low 
amplitudes, and the sural responses were normal. The PASPs were 
present and the response to repetitive stimulation of the ulnar nerve 
was normal. A needle examination of the left deltoid muscle showed 
some small myopathic units but no fibrillation potentials.
Patient III:18
Consistent with her sisters, this 63-year-old woman had noted 
ptosis at the age of 40 years and started complaining of dysphagia 
approximately 10 years later. She had had eyelid repair operations 
at least 15 years previously, and had also had oesophageal sphincter 
botulinum toxin injections and myotomy for severe dysphagia at the 
age of 56. She did not complain of limb muscle weakness. However, 
she noted that she had felt tired after bypass surgery following a 
myocardial infarction 2 months prior to her visit to neurology. On 
examination, her higher mental functions were normal (MMSE 
30/30). She had very mild limitation of upward and lateral gaze, and 
a mild dysarthria was noticeable. Orbicularis oculi muscle power 
was slightly decreased and mild ptosis was present. Power of the 
latissimus dorsi and hip extensors was mildly reduced (4+/5), deep 
tendon reflexes in the upper limbs were a flicker with augmentation, 
the patella reflex was 2+/4, and the ankle reflexes were absent 
bilaterally. Findings on sensory examination and the co-ordination 
and gait were normal.
On EMG, the peroneal, tibial and radial motor responses as well as 
the response to repetitive stimulation of the ulnar nerve were normal, 
and PASPs were present. The amplitude of the medial and lateral 
plantar responses was somewhat decreased, but conduction velocities 
were normal. The amplitude of the sural response was also slightly 
decreased at point A. A needle examination showed normal muscle 
unit potentials in the deltoid muscle.
Molecular analysis
As shown in Fig. 2, cycle sequencing of exon 1 of the PABPN1 gene 
of the three patients (III:14, III:17 and III:18) from whom blood 
samples were available revealed that they were heterozygous for 
a (GCG)11(GCA)3GCG or (GCN)15 mutant allele. This expansion 
therefore increases the total number of alanine residues (GCNs) from 
the normal ten to 15.
Discussion
We describe the first SA Afrikaner family with genetically proven 
OPMD. The Afrikaners are mainly descended from Dutch, German 
and some French immigrants to the Cape during the 17th century. 
It is estimated that the founding Afrikaner population consisted of 
approximately 90 families by 1687. We therefore expected to find 
that our family would share a mutation with one of these founding 
populations. Many individuals with OPMD from North America 
and Europe carry a mutant (GCG)9 or (GCN)13 allele.[3] Studies from 
the UK showed an equal distribution of (GCG)9 and (GCG)10 (or 
(GCN)13 and (GCN)14) mutations,[10] and in Hispanic New Mexicans, 
the (GCG)9 mutation was also commonly identified.[11]
Our SA Afrikaner family has the (GCG)11(GCA)3GCG (or (GCN)15) 
mutation, which has been established to be a founder mutation 
in Uruguayan and Mexican families.[12] Both the genealogical and 
molecular data suggested that the ancestors of the Uruguayan 
population with OPMD were settlers in the Canary Islands in 
the 19th century,[12] with the possibility that the mutation arose 
between the 10th and 14th centuries in the Old World. In the 
Mexican population, the possibility of two independent founder 
effects has been suggested, since the (GCG)11(GCA)3GCG (or 
(GCN)15) and (GCG)9 or (GCN)13 mutant alleles both occurred in 
the investigated patients.[13] Interestingly, in the study from Uruguay, 
one of the patients was an individual from SA who also carried the 
(GCG)11(GCA)3GCG (or (GCN)15) mutation, but no further details 
on this patient are available.
The patients in the current study presented with typical symptoms 
and signs of autosomal dominant OPMD. Ptosis started around the 
age of 40 years, closely followed by progressive dysphagia. Corrective 
surgery for ptosis was performed on three patients, and one also had 
oesophageal surgery. The mutant (GCG)11(GCA)3GCG (or (GCN)15) 
allele may be associated with an earlier onset of symptoms, specifically 
ptosis, than the mutant (GCG)9 or (GCN)13 allele. Our patients 
reported an onset of ptosis at around 40 years, which has also been 
described in the Mexican population, where the mean age at onset 
of ptosis was 46.5 years in subjects with the (GCG)11(GCA)3GCG 
(or (GCN)15) mutation, compared with 54.7 years in those with the 
(GCG)9 or (GCN)13 mutation.[13] All patients showed signs of external 
ophthalmoplegia, which was severe in two cases.
Additionally, all patients had dysarthria, which ranged from very 
mild to moderate. Dysarthria is a finding that has been reported 
in patients with OPMD, but is rarely emphasised. A study by 
Young and Durant-Jones[14] evaluated voice intensity, resonance 
and pitch range in five patients with OPMD, showing changes in 
voice, articulation and resonance in all individuals, which was 
worse in those older than 70 years. Hyper-nasality, as a finding 
of the dysarthria, was reported in three of their patients. Of our 
four patients, the older two, at 70 and 75 years, also had the worst 
dysarthria. Mild proximal weakness, often described in OPMD, 
was noted in all our patients and neck flexion weakness in two. 
Interestingly, two of our patients also showed mild weakness of the 
tibialis anterior muscles, and one of the older patients also had clear 
weakness of finger extension, uncommonly seen in OPMD. The 
high foot arches in two patients and the absent ankle reflexes raised 
the clinical possibility of a peripheral neuropathy.
On electrophysiological studies, clear myopathic units were seen 
in two of our patients, and findings on all motor nerve conduction 
studies were normal. Low amplitudes of the medial and lateral 
plantar responses were noted in the three patients in whom these 
were tested, but the abnormalities were mild; in two, the amplitudes 
of the sural nerve responses were also minimally reduced. 
Involvement of the peripheral nerves in OPMD has been debated 
in the past decade. Finsterer[15] concluded in a recent editorial that 
involvement of peripheral nerves in OPMD should be evaluated 
further by studying only patients with genetically confirmed 
OPMD, since many of the patients with electrophysiological 
abnormalities were reported in the pre-genetic era. The significance 
of our electrophysiological findings is unclear; motor nerves and 
autonomic responses were not involved electrophysiologically, 
and if anything the lower amplitudes of the plantar responses may 
indicate a mild sensory neuropathy. However, all our patients 
were older than 60 years, age perhaps influencing the amplitude 
of sensory nerve responses, although the medial plantar responses 
should not be absent before the age of 70 years.
Conclusion
In conclusion, we have described the clinical and genetic features of 
the first SA family with OPMD.
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